Connect with us

Technology

Caris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Overall Survival Compared to Estimates from Targeted Gene Panels

Published

on

Targeted gene panels miscalculate tumor mutational burden in 10–15% of patients, directly resulting in incorrect pembrolizumab eligibility determination

IRVING, Texas, May 11, 2026 /PRNewswire/ — Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a study in Cancer Immunology, Immunotherapy demonstrating that measuring tumor mutational burden (TMB) using ultra-deep Whole Exome Sequencing (WES) provides superior prediction of pembrolizumab immunotherapy benefit compared to estimates of TMB from targeted gene panels. TMB is a pan-tumor biomarker used to determine patients’ eligibility for pembrolizumab. These findings highlight the importance of testing all cancer patients with ultra-deep WES, the only truly comprehensive genomic profile for therapy selection.

The study used Caris’ large-scale, real-world clinico-genomic database, containing 26,756 patients treated with pembrolizumab who were evaluable for this study. WES provides a true measurement of TMB by interrogating every protein-coding gene mutation that may create a neoantigen, in comparison to targeted panels that only estimate TMB with incomplete gene coverage.

Key findings include:

The analysis compared WES-measured TMB with commercially available targeted panel estimates of TMB and found discordance in 10-15% of cases, with error rates correlating to panel size.

In discordant cases, WES TMB more accurately predicted overall survival in pembrolizumab-treated patients than panel-based estimates.

In a subset of ‘TMB reliant’ patients (n = 3,981), for example, patients with tumor types that lack disease-specific immune checkpoint inhibitor indications, the median overall survival in discordant cases was about five months longer for WES TMB-High and panel TMB-Low compared to WES TMB-Low and panel TMB-High cases treated with pembrolizumab.

“These findings underscore the critical importance of using Whole Exome Sequencing to guide immunotherapy decisions,” said Milan Radovich, PhD, Senior Vice President, Chief Scientific Officer at Caris. “Whole Exome Sequencing is the gold-standard for determination of tumor mutational burden, ensuring that patients who stand to benefit from pembrolizumab are correctly identified and that those unlikely to respond are not exposed to unnecessary treatment.”

The study concludes that WES-based TMB measurements are a superior predictor of pembrolizumab benefit than panel-based TMB estimates and more reliably identify both patients who may benefit from therapy and those unlikely to respond, particularly in tumor types where TMB is the primary biomarker guiding access to immune checkpoint inhibitors.

Caris received FDA approval in November 2024 for MI Cancer Seek. This tissue-based assay is the first and only simultaneous WES and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved companion diagnostic (CDx) indications for molecular profiling of solid tumors and includes quantitative reporting of TMB.

About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.  

Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.  

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or similar expressions.   

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” and elsewhere in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law. 

Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606

View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-publishes-study-showing-whole-exome-measurement-of-tumor-mutational-burden-results-in-increased-overall-survival-compared-to-estimates-from-targeted-gene-panels-302768392.html

SOURCE Caris Life Sciences

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Datex and Elastic Solutions Survey Suggests 3PL Competitive Advantage Is Shifting from Technology Adoption to Execution

Published

on

By

100+ 3PL professionals reveal a growing gap between technology adoption and measurable value, with throughput gains widespread but ROI confidence still limited

CLEARWATER, Fla., Aug. 25, 2026 /PRNewswire/ — Datex, a leading provider of third-party logistics (3PL) warehouse management software (WMS) for complex and regulated storage environments, today released findings from The 3PL AI & Automation Playbook Survey, based on original research conducted by Elastic Solutions and sponsored by Datex. The survey gathered insights from more than 100 3PL logistics, supply chain and warehousing professionals across North America.

The findings point to a shift in the 3PL technology conversation. As adoption of AI and automation grows, simply having the technology may no longer be enough to differentiate. The greater opportunity is in execution: how effectively 3PLs turn those investments into better warehouse performance, measurable business value and stronger customer service. This closely reflects the brief’s central finding that differentiation is shifting from technology adoption to operational execution.

The data illustrates both the progress 3PLs are making and the execution challenges that remain. While 83% of respondents reported increased warehouse throughput from automation and advanced WMS capabilities, only 33% said they are confident or very confident they will achieve positive ROI within their projected implementation timeline. At the same time, 80% said customers expect, or increasingly assume, AI and automation capabilities from their 3PL partners.

The survey also points to a shift in what is driving investment. Among respondents, 84% cited operational efficiency, evolving client demands or competitive advantage as the primary reason for investing in AI and automation, compared with just 6% who primarily cited labor shortages and rising labor costs.

“Competitive advantage doesn’t come from simply having more technology. It comes from what you can accomplish with it,” said Mike Armanious, CEO of Datex. “For 3PLs, the opportunity is to start with the business outcome and make sure every investment contributes to a better operation, whether that means greater productivity, stronger service or the ability to respond faster to new customer requirements. Sometimes that means getting more from the technology you already have. Other times, it means recognizing when the foundation itself needs to change.”

The resulting executive brief, The Execution Advantage, looks at what the survey findings may mean for 3PLs as they continue investing in AI, automation and warehouse technology, including considerations around ROI, workforce productivity, changing customer expectations and the role of the WMS in supporting these initiatives.

The findings represent the perspectives of more than 100 survey respondents and should be viewed as a snapshot of their experiences and priorities rather than a representation of the entire 3PL market.

Download the full executive brief, The Execution Advantage: How AI, Automation, and Modern WMS Platforms Are Shaping the Next Competitive Advantage for 3PLs, here.

About Datex
Datex helps third-party logistics providers simplify the complexity of multi-client warehouse operations. Footprint® WMS combines real-time inventory visibility, client-specific workflows, advanced billing and low-code configurability to help 3PLs operate more efficiently and adapt faster. Complemented by Footprint Analytics and Datex Studio, the platform delivers trusted insights, streamlined operations and seamless integration. The result is greater agility, stronger customer service and a foundation for scalable growth.

For more information, visit https://datexcorp.com/.

About Elastic Solutions
Elastic Solutions is a leader in targeted marketing, research and demand generation services for the B2B high-tech community. Elastic Solutions was responsible for generating and analyzing the data presented in the executive brief.

For more information, visit www.elasticroi.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/datex-and-elastic-solutions-survey-suggests-3pl-competitive-advantage-is-shifting-from-technology-adoption-to-execution-302859647.html

SOURCE Datex Inc.

Continue Reading

Technology

ECRI Expands Problem Reporting Network and Calls for More Data on AI Errors in Patient Care

Published

on

By

As the adoption of AI in healthcare continues to accelerate, ECRI calls on healthcare providers, systems, and clinicians nationwide to report AI-related incidents

FORT WASHINGTON, Pa., Aug. 25, 2026 /PRNewswire/ — Global patient safety nonprofit ECRI announced an expansion of its Problem Reporting Network to specifically capture and investigate errors, malfunctions, and near misses involving artificial intelligence (AI) tools and AI-enabled devices used in patient care.

ECRI is calling on healthcare providers, health systems, and clinicians nationwide to submit reports of any incident where an AI-enabled tool may have contributed to an error or introduced risk into care delivery. ECRI triages and investigates those reports and shares findings with each submitter. This program compliments the ECRI and ISMP Patient Safety Organization (PSO) which has gathered and analyzes more than 8 million reports of safety events from healthcare providers nationwide.

AI’s promise comes with a data gap

AI is actively transforming healthcare, with immense potential to improve clinical outcomes and efficiency. However, clinical AI tools and AI-enabled medical devices are being deployed at a pace that has challenged the safeguards designed to prevent, identify, and respond to failures.

AI now assists with everything from diagnostic imaging and clinical decision support to personal chatbots, but there is no centralized, healthcare-specific mechanism tracking how often these tools produce incorrect or misleading outputs, and how often those outputs reach a patient.

“ECRI has persistently emphasized the risk of adopting AI with insufficient scrutiny,” said Scott Lucas, PhD, ECRI’s Vice President of Devices, Therapeutics, and Technology. “Although we appreciate AI’s tremendous potential, we don’t yet have a clear picture of its downstream impact in healthcare. Without a robust reporting dataset and analysis, the industry cannot sufficiently improve the design and integration of AI tools and devices. We must look to evidence and data to understand the evolving risks and associated system factors, to enable the use of the safest, most effective technologies.”

Survey shows a mix of AI errors & uncertainty  

In a recent ECRI survey of 124 respondents — mostly quality, safety, risk or compliance leaders — nearly one-third said they encountered an AI output they believed was incorrect or misleading over the past year (31%), while 34% had not, and 35% were unsure. Nine percent reported an AI error reached a patient or impacted a care decision. Ambient scribes were the most commonly encountered AI tools in the survey (37%), ahead of EHR-embedded clinical decision support (31%) and clinical LLM assistants or chatbots (31%).

ECRI has evaluated the effectiveness and clinical evidence surrounding numerous AI-enabled devices and AI tools, including applications in imaging, fall prevention, anesthesia, wearable technology for chronic disease management, cardiovascular diagnoses, colonoscopy systems, and behavioral therapy.

How ECRI’s Problem Reporting Network works

ECRI’s Problem Reporting Network has served the healthcare community since 1972, offering a free, confidential channel for reporting medical device and technology problems. Every submission is triaged and investigated by ECRI’s clinical and engineering experts, and ECRI follows up directly with the submitter to share what was found.

When a safety risk is identified in a device or technology, ECRI informs relevant stakeholders including manufacturers, providers, and regulatory agencies by issuing hazard reports that describe the problem and provide actionable recommendations to reduce risk. The Problem Reporting Network also contributes to the top health technology hazards and patient safety concerns in research reports ECRI publishes for the public each year.

With this most recent expansion, the Problem Reporting Network now explicitly includes a pathway for reporting suspected AI-related errors, incorrect outputs, or unsafe AI behavior encountered in clinical or operational use. Healthcare providers, systems, and professionals who have encountered a suspected AI error, whether it reached a patient or was caught beforehand, are encouraged to submit reports through ECRI’s Problem Reporting Network. 

In addition, ECRI encourages healthcare organizations to submit safety reports through all applicable required reporting channels, including state and federal reporting, and through Patient Safety Organizations.

For more information about the safe use of AI in healthcare, visit ECRI’s AI Resource Hub.

About ECRI

ECRI is an independent, nonprofit organization improving the safety, quality, and cost-effectiveness of care across all healthcare settings. Over the past six decades, ECRI has built its reputation on integrity and disciplined rigor, with an unwavering commitment to independence and evidence-based insights. ECRI is designated an Evidence-based Practice Center by the U.S. Agency for Healthcare Research and Quality. The ECRI and Institute for Safe Medication Practices PSO is a federally certified Patient Safety Organization (PSO) as designated by the U.S. Department of Health and Human Services. ECRI is the only organization worldwide to conduct independent medical device evaluations. ECRI acquired The Institute for Safe Medication Practices (ISMP) in 2020 to address one of the most prolific causes of preventable harm in healthcare, medication errors; then acquired The Just Culture Company in 2024 to transform healthcare workplace cultures – thus creating one of the largest healthcare quality and safety entities in the world.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ecri-expands-problem-reporting-network-and-calls-for-more-data-on-ai-errors-in-patient-care-302859649.html

SOURCE ECRI

Continue Reading

Technology

Murrieta the Gem of the Valley TV Series Spotlights Southern California Real Estate and Lifestyle on REAL Shows Network

Published

on

By

Locally hosted series led by Tiffany Williams highlights the people, neighborhoods, businesses, and stories that make Murrieta the Gem of the Valley.

PALM SPRINGS, Calif., Aug. 25, 2026 /PRNewswire/ — REAL Shows Network (RSN), the national TV platform dedicated to elevating real estate and lifestyle storytelling, has added Murrieta the Gem of the Valley, a new locally hosted series serving Southern California, to its lineup. The real estate and lifestyle TV series is hosted by local real estate leader Tiffany Williams and produced by RSN’s Emmy-nominated, Telly Award-winning team.

Viewers can learn more about the series and watch episodes of Murrieta the Gem of the Valley at realshows.tv.

The series captures the spirit of Murrieta by blending real estate, local culture, and community stories into a vibrant viewing experience. Each episode features Tiffany Williams:

Highlighting notable neighborhoods and distinctive propertiesCelebrating local businesses and community organizationsSpotlighting the people and stories that give the area its unique characterSharing insight into how real estate can help families build long-term wealth and legacy

“After nearly 30 years serving this valley, we’ve learned that real estate isn’t just about property. It’s about the people, businesses, and neighborhoods that give a place its soul,” said Tiffany Williams, host of Murrieta the Gem of the Valley. “Murrieta is truly the Gem of the Valley, and through this show, we want to spotlight those stories while teaching families how a home today can become a legacy tomorrow. Wealth via real estate isn’t just a strategy. It’s how you pass something priceless down to your children’s children.”

Murrieta the Gem of the Valley is part of REAL Shows Network’s growing lineup of locally branded series that highlight communities across the United States.

As part of RSN’s national network of locally branded shows, Murrieta the Gem of the Valley gives its host a full 30 minutes to build a recognizable, personality-driven brand while authentically representing the people and communities she serves. The show provides local organizations, including nonprofits and philanthropic initiatives, along with entrepreneurs and community influencers, a high-quality platform to share their stories through cinematic, lifestyle-driven segments.

Rooted in RSN’s mission of positive media, Murrieta the Gem of the Valley focuses on authenticity, connection, and the everyday experiences that make communities stand out. It uplifts the people, businesses, and causes that make the region extraordinary, offering viewers fresh insight along with engaging, professionally produced entertainment. High-resolution images and video clips from Murrieta the Gem of the Valley are available upon request.

About REAL Shows Network

REAL Shows Network (RSN) is a national TV network for top real estate professionals and influential local leaders, giving select hosts in each market the exclusive opportunity to lead a full 30-minute show that showcases their expertise, partners, and community. Created by an Emmy-nominated, Telly Award-winning production team, RSN delivers cinematic, lifestyle-driven storytelling and strategic media exposure that builds authority, deepens community connection, and elevates positive stories in each market. For more information, visit realshows.tv.

View original content to download multimedia:https://www.prnewswire.com/news-releases/murrieta-the-gem-of-the-valley-tv-series-spotlights-southern-california-real-estate-and-lifestyle-on-real-shows-network-302859651.html

SOURCE REAL Shows Network

Continue Reading

Trending